# OnCo record nct06018337 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06018337/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06018337", "NCT06018337" ;
  schema:name "A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre"@en ;
  schema:alternateName "DYNASTY-Breast02"@en ;
  schema:description "A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc., active."@en ;
  schema:url <https://onco.cc/trials/nct06018337/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06018337> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-01-18" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-pamirtecan/> ;
  onco:companies <https://onco.cc/companies/dualitybio/> .